Barton Shane sold $1.6M of BIOA

Barton Shane (Principal Accounting Officer) sold 62,566 shares of BioAge Labs, Inc. (BIOA) at an average of $25.20 ($25.19–$25.21, $1.58M total) across 2 trades over 2026-06-29 to 2026-06-30 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Barton Shane
Published Jul 1, 2026, 8:27 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 1, 2026, 8:39 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$BIOA
Neutral
medium confidence
Mentioned
$BIOA
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$BIOANeutralLow
01

Why it matters

The newest fact is the disclosed sale size, price range, and that it was executed under a pre-arranged 10b5-1 plan, ending the officer’s direct holdings at zero.

02

Market read

This provides a fresh, primary-source datapoint on insider selling activity, but it does not introduce new operating/financial information.

03

What to watch

The officer ends with 0 shares, which can matter for sentiment, but the article lacks context on prior holdings, option exercises, or whether other insiders are buying.

Relevance 5/10Novelty 4/10Timing: filed after-hours on 2026-07-01; reflects trades dated 2026-06-29 to 2026-06-30

Background

The article is an SEC Form 4 insider transaction disclosure for BioAge Labs, Inc. (BIOA).

Company-level read

Ticker impact

$BIOANeutralMedium confidence
Context

BioAge Labs insider Form 4 shows principal accounting officer Barton Shane sold 62,566 shares for ~$1.58M at ~$25.20 (10b5-1).

Expected impact

Near-term impact likely minimal; any reaction would be sentiment-driven rather than fundamental.

Evidence & confidence

The filing is a disclosed insider sale (not a buy), but it is explicitly under a pre-arranged 10b5-1 plan and the article provides no new company fundamentals.

Market effects

No sector read-through; this is company-specific insider transaction disclosure.

None indicated.

None indicated.

Counterpoint

Because it’s a 10b5-1 plan, the sale may be purely mechanical and not a bearish signal; traders may ignore it unless paired with other negative catalysts.

Key entities

  • BioAge Labs, Inc.

    Subject of the Form 4 insider transaction disclosure.

  • Barton Shane

    Principal Accounting Officer who sold 62,566 shares under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$BIOAMedAI 8/10

Five-year data of continuous Leqembi® treatment show increasing benefit over time

BioArctic's partner Eisai presented five-year data from the Clarity AD study, showing continuous Leqembi treatment in early Alzheimer's disease increased clinical benefits over time. 62% of patients treated early showed cognitive improvement. Leqembi reduced cognitive decline by 2.05 points after five years compared to historic data. Eisai and BioArctic collaborate on Leqembi's development and commercialization.

$BIOAMed

BioAge Labs 3Q 2026: Revenue $298K, EPS ($0.73) — 10-Q Summary

BioAge Labs (BIOA) reported 3Q 2026 revenue of $298K, down 85% YoY, and a net loss of $33.5M, up 66% YoY. The decline was due to a $1.7M adjustment in Novartis collaboration revenue. R&D costs rose 63% to $30.2M, driven by BGE-102 trial and manufacturing expenses. The company completed QUELL-CV enrollment and expects topline data in 4Q 2026.

$BIOAMed

BioAge Labs Reports Third Quarter 2026 Financial Results and Provides Business Updates

BioAge Labs, Inc. (BIOA) filed an SEC Form 8-K — Results of Operations and Financial Condition. EXHIBIT 99.1 BioAge Labs Reports Third Quarter 2026 Financial Results and Provides Business Updates First participant dosed in QUELL-DME, a Phase 2 trial of BGE-102, a potential best-in-class oral NLRP3 inhibitor, in diabetic macular edema; topline results anticipated in the seco

$BIOAMed

About $352 million in cash and securities could fund BioAge's operations through 2029

BioAge Labs (NASDAQ: BIOA) reported $352M in cash and securities for operations through 2029. It dosed the first participant in a Phase 2 trial for BGE-102 in diabetic macular edema, with results expected in 2H 2027. The QUELL-CV Phase 2 trial for BGE-102 in obesity completed enrollment, with data due in 4Q 2026. The company aims to file an IND for its APJ agonist program by year-end 2026. BioAge also updated its collaborations with Novartis, Lilly, and Deep Origin.